A Look At 4 Cannabis Stocks – AGH, AC8, CAN, CPH

| June 14, 2019

article image
The Cannabis sector is comparatively broad than the expectations of various market research houses, boutique research house or asset managers etc. The prevailing status of cannabis legalisation gradually appears positive, but the market would unleash its further potential, once the legalisation gathers pace with less regulatory hesitance and smooth approval of drugs with related active ingredients. The industry size would exponentially increase as legalisation gathers pace; as of now, there are not enough countries with the full legal status of cannabis.

Spotlight

Quick'rCare

Quick’rCare is the better immediate healthcare experience for every patient. Started in 2016, we’ve worked to fix the broken systems that get in the way of good immediate care by uniting modern patients and providers. It all started when our founder was trying to give some advice to a friend to go to an immediate care facility, but neither one of them knew where to go. So they searched online and asked friend close by, but they got all kinds of answer like the hospital, the local walk in clinic, and even to go home to mom! So this founder’s friend decided to walk into the hospital hours later and came out with huge bill. From there, the light bulb went off and Quick’rCare was born.

OTHER ARTICLES
PHARMACY MARKET

A pharma outsourcing mission

Article | August 18, 2021

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | August 18, 2021

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | August 18, 2021

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | August 18, 2021

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Quick'rCare

Quick’rCare is the better immediate healthcare experience for every patient. Started in 2016, we’ve worked to fix the broken systems that get in the way of good immediate care by uniting modern patients and providers. It all started when our founder was trying to give some advice to a friend to go to an immediate care facility, but neither one of them knew where to go. So they searched online and asked friend close by, but they got all kinds of answer like the hospital, the local walk in clinic, and even to go home to mom! So this founder’s friend decided to walk into the hospital hours later and came out with huge bill. From there, the light bulb went off and Quick’rCare was born.

Events